Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNR-086 vs Ilaris in Healthy Volunteers
NCT06481189Phase 1Completed
- Sponsor
- Generium
- Start
- Sep 2022
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of GNR-086 in Cryopyrin-associated periodic syndromes (CAPS) (2 arms), sponsored by Generium. Primary endpoints: Area under the plasma concentration versus time curve at Day 120 and Peak Plasma Concentration at Day 120. Started Sep 2022; status: completed.
02
Drugs
GNR-086
03
Conditions
Cryopyrin-associated periodic syndromes (CAPS)
Beyond the preview
Go deeper on NCT06481189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06481189.